Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rilparencel (REACT) in T2DM and CKD (PROACT 2)
NCT05286853Phase 3Withdrawn
- Sponsor
- ProKidney
- Start
- Jul 2024
- Primary completion
- Sep 2024
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of rilparencel in diabetic nephropathy (DN) and chronic kidney disease (CKD) (2 arms), sponsored by ProKidney. Primary endpoint: Primary Composite Endpoint at 60 months. Planned start Jul 2024; status: withdrawn.
02
Drugs
rilparencel
03
Conditions
diabetic nephropathy (DN)chronic kidney disease (CKD)
Beyond the preview
Go deeper on NCT05286853.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05286853.